Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-21

Study Completion Date

2018-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many cancers are diagnosed after 75 years. Treatment in chemotherapy begins without evidence of geriatric risk factors. A new tool for screening for geriatric fragilities is used, a self-administered questionnaire carried out by the patient before each chemotherapy cure. The objective is to secure the quality of patient care and to detect the appearance and / or aggravation of geriatric fragilities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy

NCT02583035

Cancer Hematologic Malignancy

COMPLETED NA

Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)

NCT03059875

Surgery 75 Years Old and More Female Breast Cancer

UNKNOWN NA

Validation of a Screening Tool in Geriatric Oncology

NCT00963911

Breast Cancer Colorectal Cancer Head and Neck Cancer +3 more

COMPLETED NA

Geriatric Oncology Follow-up in the Alpine Valley

NCT03349229

Oncology Aging

UNKNOWN

Screening for Social Weaknesses and Coordination Course of Cancer Patients

NCT02369783

Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged ≥ 75 years during oncological treatment:

* Number of D-FOGs filled in: comparison with the number of patients included in the study and the number of visits of each patient.
* Regularity of the D-FOG self-questionnaire by the patient: comparison with the number of visits of the patient for a chemotherapy cure (HDJ or HDS).
* Number of criteria entered by D-FOG: comparison with the total number of criteria to be filled in
* Criterion analysis of D-FOG

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

75 Years Old and More Cancer Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group D-FOG

Filling of a self-questionnaire before each chemotherapy cure

Self-questionnaire

Intervention Type OTHER

Filling of a self-questionnaire before each chemotherapy cure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Self-questionnaire

Filling of a self-questionnaire before each chemotherapy cure

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 75 years and over
* Carriers of diagnosed cancer (excluding hematology)
* Whatever the location, uniqueness or multiple, duration of development and treatment status (adjuvant, neoadjuvant, locally advanced or metastatic)
* Seen in nursing consultant
* Beginning an oncological treatment
* Supported for oncology day hospital (HDJ) or weekly (HDS) chemotherapy
* Patient not opposed to participate in the study

Exclusion Criteria

* Patients under 75 years of age
* Having not had an IDE ad consultation
* During oncological treatment
* Receiving Oral Therapy or hormone therapy alone
* Treated by radiotherapy alone or surgery alone
* Not attending a day or week oncology hospital
* Refusal to participate in research

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No